This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information

ESMO, Barcelona, Spain 26-30 September 2019

Targeting NRG1-fusions in multiple tumour types: Afatinib as a novel potential treatment option

Michaël Duruisseaux, Janessa J. Laskin, Khaled Tolba, Eva Branden, Yasushi Goto, Robert C. Doebele, Parneet Kaur Cheema, Jacques Cadranel, Martin R. Jones, Alexander E. Drilon, Domenico Trombetta, Lucia A. Muscarella, Agnieszka Cseh, Flavio Solca, Stephen V. Liu 

NRG1

Related Materials

Learn more about the science behind this poster in the videos, papers and other materials below.

Targeting NRG1-fusions in lung adenocarcinoma: afatinib as a novel potential treatment strategy

Weinberg et al. ESMO-WCGC 2019 P-291

Neuregulin 1 Fusion–Positive NSCLC

Misako Nagasaka, MD, Sai-Hong Ignatius Ou, MD, PhDc,

FOR HEALTHCARE PROFESSIONALS ONLY.

image